BioCentury
ARTICLE | Finance

Ready to go solo

Achillion's $126 million follow-on prepares HCV play to go it alone

February 25, 2013 8:00 AM UTC

Investors hoping Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) would be taken out in the HCV gold rush might take last week's $126 million follow-on as a signal that the company now expects to go it alone for the foreseeable future.

In November 2011, President and CEO Michael Kishbauch told Bloomberg the company was in advanced discussions with potential partners and acquirers. The comment triggered an 8% jump in Achillion shares...